GlassScriptPhysician profile
Sadasivareddy Goli
NPI 1831100676
$4,742.06
in general payments reported to CMS, 2019-2025
28 companies · $570 in 2025
The $570 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $415 · 2020: $898 · 2021: $775 · 2022: $856 · 2023: $555 · 2024: $672 · 2025: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,797.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,378.52 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $445.24 | 2020-2025 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $339.81 | 2022-2025 | |
| Lilly USA, LLC | $321.82 | 2019-2025 | Jardiance, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $289.89 | 2020-2023 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $262.06 | 2019-2022 | |
| Glaxosmithkline, LLC. | $246.18 | 2020-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novartis Pharmaceuticals Corporation | $180.87 | 2019-2023 | |
| Exact Sciences Corporation | $172.43 | 2023-2025 | Cologuard Collection Kit |
| Paratek Pharmaceuticals, INC. | $171.18 | 2020-2021 | |
| Amgen INC. | $140.01 | 2023-2024 | Krystexxa, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $116.12 | 2021-2022 | |
| Pfizer INC. | $111.30 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $94.42 | 2023 | Lifevest |
| Arbor Pharmaceuticals, INC. | $80.64 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $62.73 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Kowa Pharmaceuticals America, INC. | $48.97 | 2024-2025 | Zoryve |
| Ironwood Pharmaceuticals, INC | $42.49 | 2021-2022 | |
| Astellas Pharma US INC | $39.18 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $30.19 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.18 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $28.70 | 2020 | |
| Xeris Pharmaceuticals, INC. | $22.77 | 2023 | Gvoke Hypopen |
| Horizon Therapeutics Plc | $22.35 | 2023 | Krystexxa |
| Esperion Therapeutics, INC. | $19.29 | 2021 | |
| Abbvie INC. | $16.55 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $15.35 | 2025 | Rexulti |
| Allergan, INC. | $12.82 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sadasivareddy Goli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.